FibroBiologics (FBLG) Short term Debt (2026)
FibroBiologics' (FBLG) quarterly Short term Debt came in at $124000.0 in Q2 2026, down 49.59% quarter-over-quarter from $246000.0 in Q1 2026.
Powered by 
Analysis
FibroBiologics (FBLG) Short term Debt (2026) Analysis & Trends
FibroBiologics (FBLG) has reported Short term Debt for 1 consecutive years, with $124000.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | FibroBiologics | 10.91 Mn | 10.91 Mn | - |